|Bid||4.5500 x 1200|
|Ask||4.8600 x 1800|
|Day's range||4.5300 - 4.7100|
|52-week range||2.9400 - 9.7900|
|Beta (5Y monthly)||0.24|
|PE ratio (TTM)||N/A|
|Earnings date||07 Aug 2023 - 11 Aug 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||4.00|
Every investor in Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ) should be aware of the most powerful shareholder groups...
The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that...
Atea Pharmaceuticals, Inc. (AVIR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
The heavy selling pressure might have exhausted for Atea Pharmaceuticals, Inc. (AVIR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Atea Pharmaceuticals (AVIR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Novo Nordisk (NVO) reports better-than-expected Q3 results. Sales are aided by growth in Diabetes and Obesity Care on higher GLP-1 revenues.
Looking at Atea Pharmaceuticals, Inc.'s ( NASDAQ:AVIR ) insider transactions over the last year, we can see that...
Atea Pharmaceuticals (AVIR) obtains Fast Track Designation in the United States for AT-752 for the treatment of dengue virus infection.
If you want to know who really controls Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ), then you'll have to look at the...
With me today from Atea are chief executive officer and founder, Dr. Before we begin the call, as outlined on Slide 2, I would like to remind you that today's discussion will contain forward-looking statements that involve risks and uncertainties.
Atea Pharmaceuticals, Inc. (AVIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Most readers would already be aware that Atea Pharmaceuticals' (NASDAQ:AVIR) stock increased significantly by 11% over...
The bear market is slamming biotech stocks as hard as any. Shares of the industry-tracking SPDR S&P Biotech ETF (NYSEMKT: XBI) are down by more than 33% so far this year, and its five-year total return is just below breakeven thanks to its dramatic collapse in 2021. With sentiment about biotech so persistently bad, bargain-hunting investors should be on the prowl, as there are bound to be a few diamonds in the rough out there.
It is doubtless a positive to see that the Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ) share price has gained some 33...